Last updated on April 16, 2014 at 4:43 EDT

Latest Immunomodulation therapy Stories

2014-02-10 12:26:14

GOSSELIES, Belgium, February 10, 2014 /PRNewswire/ -- iTeos Therapeutics SA today announced the filing of the Company's first patent applications protecting proprietary inhibitors of the intracellular enzyme TDO2, which is expressed at high levels in specific cancers. iTeos Therapeutics has collaborated with Ludwig Cancer Research over the last year to identify small molecule inhibitors of the enzyme that display nanomolar potency, good selectivity, favorable pharmacokinetics...

2012-10-08 07:24:18

BALTIMORE, Oct. 8, 2012 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceuticals company creating new therapies for cancer and immune / inflammatory disorders, today announced that it has raised $4.9 million in Series B Financing. Baxter Ventures, an initiative created in 2011 by Baxter International Inc., led the Series B raise and is joined by existing investors. With the funding, Gliknik will further advance towards the clinic its IVIG-mimetic lead compound, GL-2045,...